What lessons does the OxyContin story hold?
OxyContin shows that a drug's marketing — not only its chemistry — can shape a public health crisis; that criminal penalties without prison time did not change behaviour; and that supply-side fixes like reformulation can backfire when dependence is already widespread.
OxyContin illustrates how a drug's marketing, not only its chemistry, can shape a public health crisis. Purdue's claims about lower addiction risk, its 12-hour dosing message, its push towards higher doses, and its use of consultants and electronic health record prompts to boost prescribing are now well documented through court admissions and litigation. It also shows the limits of enforcement: the 2007 penalties did not stop sales growth, the 2020 penalties went largely uncollected, and no individual owner faced criminal charges. Finally, the 2010 reformulation shows that supply-side fixes can have unintended consequences when dependence is already widespread. These lessons now inform the regulation of new drugs with abuse potential and the oversight of pharmaceutical promotion.